Abstract

Eptinezumab (Vyepti) is a new CGRP monoclonal antibody for migraine prophylaxis that is administered by intravenous infusion. This article discusses its place in therapy, clinical trial efficacy and adverse effects.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call